Dr. Richard Larivière is a professor in the Department of Medicine at Laval University, and a researcher within the Endocrinology and Nephrology axis of the CHU of Quebec Research Centre. He is also Director of Master’s and PhD programs in Clinical and Biomedical Sciences of the Faculty of Medicine at Laval University. Following his doctoral studies in Clinical Sciences (cardiovascular pharmacology) at the Université de Montréal, and postdoctoral studies in molecular endocrinology at McGill University, Dr. Larivière established himself as a professor-researcher in nephrology and hypertension at L’Hôtel-Dieu de Québec. He is an active member of the Amgen-Laval University Research Chair in Nephrology, a multidisciplinary group of fundamentalist and clinical researchers.
The main objective of Dr. Larivière’s research is to better define the mechanisms of arterial hypertension and remodeling of the blood vessel wall. More specifically, he studies the role of endothelial dysfunction, that is, factors derived from the vascular endothelium in the pathogenesis of arterial hypertension, vascular and renal damage in the case of chronic renal failure, and aging. Over the years, he has demonstrated that an imbalance in endothelial production of vasoconstrictor and vasodilator factors, as well as pro-inflammatory factors, contributes significantly to the increase of arterial pressure and rigidity by stimulating, among other things, hypertrophic remodeling and calcification of the blood vessel wall. He has also demonstrated that endothelial dysfunction can be modulated by various endocrine factors and pharmacological agents, including certain drugs. Dr. Larivière’s research uses a variety of experimental models and human tissue libraries.
10, rue McMahon
Canada G1R 2J6
Data not available
Increased ET-1 and reduced ET(B) receptor expression in uremic hypertensive rats.Journal Article
Clin Exp Hypertens, 32 (1), pp. 61-9, 2010, ISSN: 1064-1963.
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.Journal Article
Eur J Pharmacol, 607 (1-3), pp. 126-34, 2009, ISSN: 0014-2999.
Endothelial and vascular dysfunctions and insulin resistance in rats fed a high-fat, high-sucrose diet.Journal Article
Am J Physiol Heart Circ Physiol, 295 (3), pp. H1044-H1055, 2008, ISSN: 0363-6135.
Effect of erythropoietin on blood pressure and on the vascular endothelial ET-1/ETB receptor system.Journal Article
Am J Hypertens, 21 (6), pp. 639-43, 2008, ISSN: 0895-7061.
Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.Journal Article
Am J Hypertens, 19 (12), pp. 1286-92, 2006, ISSN: 0895-7061.
Endothelin is a dose-dependent trophic factor and a mitogen in small arteries in vivo.Journal Article
Cardiovasc Res, 71 (1), pp. 61-8, 2006, ISSN: 0008-6363.
Effects of high-sucrose feeding on insulin resistance and hemodynamic responses to insulin in spontaneously hypertensive rats.Journal Article
Am J Physiol Heart Circ Physiol, 290 (6), pp. H2571-81, 2006, ISSN: 0363-6135.
Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats.Journal Article
J Hypertens, 23 (10), pp. 1895-903, 2005, ISSN: 0263-6352.
Cyclooxygenase inhibition with acetylsalicylic acid unmasks a role for prostacyclin in erythropoietin-induced hypertension in uremic rats.Journal Article
Can J Physiol Pharmacol, 83 (6), pp. 467-75, 2005, ISSN: 0008-4212.
Endothelin-1 levels and cardiovascular risk factors in renal transplant patients.Journal Article
Clin Biochem, 37 (12), pp. 1072-8, 2004, ISSN: 0009-9120.
- Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Proline hydroxylase inhibitors: linking HIF-1 to arterial calcification, Subvention, Fondation canadienne du rein, Subvention de soutien à la recherche biomédicale, from 2019-07-01 to 2021-06-30
- Rôle de la dysfonction endothéliale dans le remodelage et la calcification vasculaire en insuffisance rénale chronique, Subvention, Fondation de l'Université Laval, from 2016-04-01 to 2022-03-31